Combined chemotherapy and ALA-based photodynamic therapy in leukemic murine cells

• Published in: Leukemia research Vol. 36; no. 9; pp. 1179 - 1184
• Main Authors: Diez, Berenice, Ernst, Glenda, Teijo, María Julieta, Batlle, Alcira, Hajos, Silvia, Fukuda, Haydée
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-09-2012
• Subjects: 5-Aminolevulinic acid; Aminolevulinic Acid - administration & dosage; Aminolevulinic Acid - therapeutic use; Animals; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Apoptosis - drug effects; Apoptosis - radiation effects; Cell Death - drug effects; Cell Death - radiation effects; Cell Line, Tumor; Combined Modality Therapy; Combined therapy; Doxorubicin - administration & dosage; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - radiation effects; Hematology, Oncology and Palliative Medicine; Leukemia - drug therapy; Leukemia - pathology; Leukemic cells; Mice; Multidrug resistance; Necrosis - chemically induced; Necrosis - etiology; Oxidative Stress - drug effects; Oxidative Stress - physiology; Oxidative Stress - radiation effects; Photochemotherapy - methods; Photodynamic therapy; Photosensitizing Agents - administration & dosage; Photosensitizing Agents - therapeutic use; Vincristine - administration & dosage; 5-Aminolevulinic acid; Photodynamic therapy; Combined therapy; Leukemic cells; Multidrug resistance
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2012.04.027

Abstract The effects of combined administration of doxorubicin (DOX) and vincristine (VCR), with 5-aminolevulinic acid photodynamic treatment (ALA-PDT), were analyzed in sensitive murine leukemic cell lines (LBR-) and DOX and VCR chemoresistant LBR-D160 and LBR-V160 cell lines. Low doses of DOX and VCR increased anti-cancer effect of ALA-PDT in LBR-cells. Decrease in cell survival was higher when the combination VCR + ALA-PDT was used compared to DOX + ALA-PDT. Resistant cell lines LBR-D160 and LBR-V160 were sensitive to ALA-PDT; however, no changes occured when combining therapies. Thus, ALA-PDT can overcome drug resistance and is a good candidate for using treating multidrug resistant (MDR) cells.